Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
Blood product sterilisation with 0.3% tri(n-butyl)phosphate (TNBP)/0.2% sodium cholate (CA), a combination known to permit high recovery of factor VIII and factor IX, was evaluated for its effect on hepatitis B (HBV), non-A, non-B (NANB), and human T-lymphotropic type III (HTLV-III) viruses. 2 chimpanzees received factor VIII preparations contaminated with 10(4) chimpanzee infectious doses (CID50) of HBV and treated with TNBP/CA; neither had evidence of HBV infection during 9 months follow-up, but hepatitis B surface antigen (HBsAg) developed 5 and 6 weeks, respectively, after challenge with untreated inoculum. 2 chimpanzees were similarly exposed to 10(4) CID50 of Hutchinson NANB inoculum treated with TNBP/CA; neither became infected during 26 weeks of follow-up but both had characteristic NANB-associated ultrastructural changes 3-5 weeks after exposure to untreated inoculum. 2 chimpanzees inoculated with 80 ml of TNBP/CA-treated factor VIII derived from a pool of thirteen lots obtained from five US manufacturers remained free of any evidence of NANB infection during 32 weeks of follow-up. Subsequently, NANB infection developed in both animals 3-4 weeks after exposure to untreated inoculum. Exposure of HTLV-III diluted into a factor VIII preparation to TNBP/CA inactivated greater than or equal to 10(4.2) tissue culture infective doses within 20 min at 24 degrees C.
Prince
A M
AM
Horowitz
B
B
Brotman
B
B
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D019826:Cholic Acid; D002793:Cholic Acids / Q000494:pharmacology*; D017977:Deltaretrovirus / Q000187:drug effects*; D005069:Evaluation Studies as Topic; D005169:Factor VIII / Q000008:administration & dosage; D005500:Follow-Up Studies; D015483:HIV Antibodies; D006505:Hepatitis / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects; D006526:Hepatitis C / Q000276:immunology; D006518:Hepatitis Viruses / Q000187:drug effects*; D010755:Organophosphates / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D002679:Pan troglodytes / Q000382:microbiology; D013242:Sterilization; D000637:Transaminases / Q000097:blood
D000914:Antibodies, Viral; D002793:Cholic Acids; D015483:HIV Antibodies; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens; D010755:Organophosphates; D009943:Organophosphorus Compounds; D005169:Factor VIII; C009524:tributyl phosphate; D000637:Transaminases; D019826:Cholic Acid